The low participation of generics in the drug market generates higher prices and additional annual expenses to Mexicans of 2.5 billion pesos (US$139 million), said the Federal Commission for Economic Competition (Cofece).
Commission President, Alejandra Palacios, said that they identified four distortions that prevent the greater participation of actors in the medical market: entry of generics has been slow; the expiration of patents has not generated competition; there are legal strategies to extend these patents, and entry of generics has not not translated into better prices for the consumer.
President Commissioner Palacios said that promoting the use of generics is required to improve the participation of companies in the market. Also, the industry must reduce processing times for purchases and payments of medicines in the public sector.
Full Content: Informador
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Business Secretary Calls for More Agile Competition Regulator
Feb 13, 2025 by
CPI
Germany’s Antitrust Regulator Raises Concerns Over Apple’s App Tracking Policies
Feb 13, 2025 by
CPI
$60 Billion Nissan-Honda Merger Falls Apart
Feb 13, 2025 by
CPI
DOJ Moves to End Protections for Three Regulatory Agencies
Feb 13, 2025 by
CPI
Meta to Allow Rivals to List Ads on Facebook Marketplace Following EU Fine
Feb 13, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon